Lupin Limited has informed the Exchange regarding a press release dated November 14, 2025, titled "Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere".